skip to Main Content
Biogen Announces EAP For Nusinersen Will Not Be Extended To Types 2 And 3

Biogen announces EAP for nusinersen will not be extended to types 2 and 3

Biogen announced that the Expanded Access Programme for nusinersen will not be extended to SMA types 2 and 3.

We understand many families will be bitterly disappointed by the news that Biogen’s Expanded Access Programme will not be extended more widely than for “eligible individuals with infant-onset SMA (most likely to develop SMA Type 1)”.

Biogen have set out their reasoning for this decision here.

 

Back To Top